Alex A Adjei

Alex A Adjei

UNVERIFIED PROFILE

Are you Alex A Adjei?   Register this Author

Register author
Alex A Adjei

Alex A Adjei

Publications by authors named "Alex A Adjei"

Are you Alex A Adjei?   Register this Author

100Publications

2936Reads

15Profile Views

A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.

Invest New Drugs 2019 08 31;37(4):658-665. Epub 2018 Oct 31.

Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0690-xDOI Listing
August 2019

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

Lancet Oncol 2019 Aug 26;20(8):1098-1108. Epub 2019 Jun 26.

Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, MN, USA; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30329-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669095PMC
August 2019

Current Diagnosis and Management of Small-Cell Lung Cancer.

Mayo Clin Proc 2019 Aug;94(8):1599-1622

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2019.01.034DOI Listing
August 2019

Lung Cancer Worldwide.

Authors:
Alex A Adjei

J Thorac Oncol 2019 Jun;14(6):956

Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.04.001DOI Listing
June 2019

Progress in the Diagnosis and Treatment of Thoracic Malignancies Continues Unabated.

Authors:
Alex A Adjei

J Thorac Oncol 2019 May;14(5):757

Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.022DOI Listing
May 2019

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies.

J Thorac Oncol 2019 Mar 30;14(3):358-376. Epub 2018 Dec 30.

Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.034DOI Listing
March 2019

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.

J Thorac Oncol 2018 11 4;13(11):1625-1637. Epub 2018 Sep 4.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.08.2019DOI Listing
November 2018

Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.

Lung Cancer 2018 08 19;122:214-219. Epub 2018 Jun 19.

Division of Hematology, Mayo Clinic, Rochester, MN, United States; Robert D. & Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.06.025DOI Listing
August 2018

WITHDRAWN: What is a "High-Impact" Journal?

Authors:
Alex A Adjei

J Thorac Oncol 2018 Aug 26. Epub 2018 Aug 26.

Mayo Clinic, Rochester, New York.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183081
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.07.018DOI Listing
August 2018

2017-A Banner Year for Thoracic Oncology.

Authors:
Alex A Adjei

J Thorac Oncol 2018 03;13(3):290

Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.01.014DOI Listing
March 2018

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

Transl Lung Cancer Res 2017 Dec;6(Suppl 1):S41-S43

Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.10.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750158PMC
December 2017

Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.

J Thorac Oncol 2017 11;12(11):1603-1605

Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.09.091DOI Listing
November 2017

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

J Clin Oncol 2017 Oct 30;35(30):3391-3400. Epub 2017 Aug 30.

Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGovern, John Black, Travis Dockter, Tufia Haddad, Charles Erlichman, Alex A. Adjei, Dan Visscher, Benjamin R. Kipp, Minetta C. Liu, John R. Hawse, Matthew M. Ames, and James N. Ingle, Mayo Clinic, Rochester, MN; Zachary R. Chalmers and Garrett Frampton, Foundation Medicine, Cambridge, MA; and John R. Hawse, James H. Doroshow, Jerry M. Collins, and Howard Streicher, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.3246
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648176PMC
October 2017

The Journal of Thoracic Oncology Achieves a New Benchmark.

Authors:
Alex A Adjei

J Thorac Oncol 2017 09;12(9):1334

Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.007DOI Listing
September 2017

Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.

J Thorac Oncol 2017 04;12(4):602-606

Department of Oncology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.025DOI Listing
April 2017

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

J Thorac Oncol 2016 12;11(12):2048-2050

Department of Oncology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.008DOI Listing
December 2016

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

J Clin Oncol 2016 11 30;34(33):3992-3999. Epub 2016 Sep 30.

Herbert H. Pang and Perry Cheng, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region, People's Republic of China; Herbert H. Pang, Xiaofei Wang, Ying Zhang, Thomas E. Stinchcombe, and Harvey J. Cohen, Duke University School of Medicine, Durham, NC; Melisa L. Wong, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco; David Gandara, University of California, Davis Comprehensive Cancer Center, Sacramento, CA; Apar Kishor Ganti, Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE; Daniel J. Sargent and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; Chen Hu, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Chen Hu, Johns Hopkins University School of Medicine, Baltimore, MD; Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, WA; Judith B. Manola, Dana-Farber Cancer Institute, Boston, MA; Richard L. Schilsky, ASCO, Alexandria, VA; Jeffrey D. Bradley, Washington University School of Medicine, St Louis, MO; Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY; Suresh S. Ramalingam, The Winship Cancer Institute of Emory University, Atlanta, GA; and Everett E. Vokes, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.7088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477832PMC
November 2016

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Br J Cancer 2016 07 23;115(2):203-11. Epub 2016 Jun 23.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947704PMC
July 2016

The Journal of Thoracic Oncology in the Next Decade.

Authors:
Alex A Adjei

J Thorac Oncol 2016 Jan;11(1)

Roswell Park Cancer Institute, Buffalo, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.10.012DOI Listing
January 2016

FGFR Signaling as a Target for Lung Cancer Therapy.

J Thorac Oncol 2016 Jan;11(1):9-20

Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.08.003DOI Listing
January 2016

A Milestone for the Journal of Thoracic Oncology.

Authors:
Alex A Adjei

J Thorac Oncol 2015 Dec;10(12):1666

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000697DOI Listing
December 2015

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Oct;10(10):1396-403

*Service d'oncologie médicale, Département d'oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; and †Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000644DOI Listing
October 2015

Toward High-Precision Genomic Biomarkers: The Importance of Context.

J Thorac Oncol 2015 Sep;10(9):1237-1239

Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000633DOI Listing
September 2015

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1099-106

*Division of Biomedical Statistics and Informatics, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; †Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona; ‡Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; §Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University, Durham, North Carolina; ‖Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, NCIC Clinical Trials Group, Queen' University, Kingston, ON, Canada; #Department of Hematology & Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia; **Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California; ††Department of Statistics for the Data Center/Operations Office, Japan Clinical Oncology Group Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan; ‡‡Department of Medical Oncology, Japanese Society of Medical Oncology, Tokyo, Japan; §§Department of Medicine, The University of Chicago Medicine and Biologic Sciences Center, Chicago, Illinois; and ‖‖Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153349
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493926PMC
July 2015

New strategies to develop new medications for lung cancer and metastasis.

Cancer Metastasis Rev 2015 Jun;34(2):265-75

Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10555-015-95
Web Search
http://link.springer.com/10.1007/s10555-015-9553-5
Publisher Site
http://dx.doi.org/10.1007/s10555-015-9553-5DOI Listing
June 2015

Lung cancer and metastasis: new opportunities and challenges.

Cancer Metastasis Rev 2015 Jun;34(2):169-71

Zhongshan Hospital, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Biomedical Research Center, Shanghai, China,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10555-015-9562-4
Publisher Site
http://dx.doi.org/10.1007/s10555-015-9562-4DOI Listing
June 2015

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Oncologist 2015 Jun 22;20(6):660-73. Epub 2015 May 22.

Roswell Park Cancer Institute, Buffalo, New York, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571783PMC
June 2015

Targeting oncogenic drivers.

Prog Tumor Res 2014 17;41:1-14. Epub 2014 Feb 17.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, N.Y., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000355895DOI Listing
April 2015

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Invest New Drugs 2015 Apr 3;33(2):432-9. Epub 2015 Feb 3.

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0207-9DOI Listing
April 2015

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

J Thorac Oncol 2015 Jan;10(1):172-80

*Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; †Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; ‡Illinois CancerCare, Peoria, IL; §Hematology/Oncology and **Radiation Oncology, Mayo Clinic, Scottsdale, AZ; ‖Carle Cancer Center Community Clinical Oncology Program, Urbana, IL; ¶Wichita Community Clinical Oncology Program, Wichita, KS; #Oncology and ‡‡Laboratory Medicine and Pathology, and Anatomic Pathology, Mayo Clinic, Rochester, MN; and ††Upstate Carolina CCOP, Spartanburg, SC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320011PMC
January 2015

Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Nat Rev Clin Oncol 2015 Jan 2;12(1):8-10. Epub 2014 Dec 2.

Roswell Park Cancer Institute, Elm &Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.212DOI Listing
January 2015

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

Cancer Treat Rev 2014 Sep 1;40(8):917-26. Epub 2014 Jul 1.

Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.06.010DOI Listing
September 2014

A note from the Editor-in-Chief on enhancements to the journal.

Authors:
Alex A Adjei

J Thorac Oncol 2014 Sep;9(9):1236

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000325DOI Listing
September 2014

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.

J Thorac Oncol 2014 Aug;9(8):1146-53

*Roswell Park Cancer Institute, Buffalo, NY; †Mayo Clinic Rochester, MN 55905; ‡Michiana Hematology Oncology, South Bend, IN; §Illinois CancerCare, Ottawa, IL; ‖Mayo Clinic Scottsdale, AZ; ¶Missouri Valley Cancer Consortium, Omaha, NE; and #Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145612PMC
August 2014

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

Cancer Treat Rev 2014 Jul 24;40(6):750-9. Epub 2014 Feb 24.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372140002
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2014.02.003DOI Listing
July 2014

The clinical development of MEK inhibitors.

Nat Rev Clin Oncol 2014 Jul 20;11(7):385-400. Epub 2014 May 20.

Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2014.83
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2014.83DOI Listing
July 2014

ALK inhibitors in the treatment of advanced NSCLC.

Cancer Treat Rev 2014 Mar 7;40(2):300-6. Epub 2013 Aug 7.

Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.07.002DOI Listing
March 2014

Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Mar;9(3):e24-6

*Infectious Diseases Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; †Oncology Department, Fribourg Hospital and Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne; Switzerland; ‡Roswell Park Cancer Institute, Buffalo, New York; §Radiology Department, ‖Microbiology Institute, and ¶Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000018DOI Listing
March 2014

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.

J Thorac Oncol 2014 Feb;9(2):222-30

*Roswell Park Cancer Institute, Buffalo, New York; †The Oncology Institute of Hope and Innovation, Anaheim, California; ‡Rochester General Hospital, Rochester, New York; and §Department of Medicine, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000062DOI Listing
February 2014

Strategies for improving outcomes in NSCLC: a look to the future.

Lung Cancer 2013 Dec 8;82(3):375-82. Epub 2013 Sep 8.

Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.025DOI Listing
December 2013

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Anticancer Drugs 2013 Nov;24(10):1079-83

aDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota bDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida cDepartment of Internal Medicine, Greater Baltimore Medical Center, Baltimore, Maryland dDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937851PMC
November 2013

Lung cancer-celebrating progress and acknowledging challenges.

Authors:
Alex A Adjei

J Thorac Oncol 2013 Nov;8(11):1350-1

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000008DOI Listing
November 2013

Understanding, recognizing, and managing toxicities of targeted anticancer therapies.

CA Cancer J Clin 2013 Jul-Aug;63(4):249-79. Epub 2013 May 28.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21184DOI Listing
September 2013

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Invest New Drugs 2013 Aug 8;31(4):891-9. Epub 2012 Nov 8.

Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9887-6DOI Listing
August 2013

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Invest New Drugs 2013 Aug 30;31(4):967-73. Epub 2013 Jan 30.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10637-013-99
Web Search
http://link.springer.com/10.1007/s10637-013-9929-8
Publisher Site
http://dx.doi.org/10.1007/s10637-013-9929-8DOI Listing
August 2013

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Cancer 2012 Nov 20;118(21):5358-65. Epub 2012 Mar 20.

Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481159PMC
November 2012

MET: a promising anticancer therapeutic target.

Nat Rev Clin Oncol 2012 May 8;9(6):314-26. Epub 2012 May 8.

Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, CH1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.71DOI Listing
May 2012

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs.

Ther Adv Med Oncol 2011 Nov;3(1 Suppl):S37-50

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834011423403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225020PMC
November 2011

Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.

Liver Int 2010 Nov 8;30(10):1522-8. Epub 2010 Sep 8.

Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1478-3231.2010.02336.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042145PMC
November 2010